Hg tops $1 billion invested in healthcare globally with this transaction.
Healthcare technology company Hg announced a finalized agreement Thursday to acquire global medical imaging software and enterprise workflow solution provider Intelerad Medical Systems.
The details of the agreement, including the purchase price, are undisclosed. The transaction is expected to be complete by the end of the first quarter of 2020 following customary regulatory approvals.
This move marks Hg’s fifth major investment into healthcare technology, bringing its overall investment globally to more than $1 billion. The investment, the company’s first in Canada, will be made from the Hg Genesis 8 Fund. Under the terms of this agreement, Hg will acquire Canadian-based Intelerad from Novacap’s TMT IV Fund, as well as its founders, management, and employee shareholders who will all be re-investing into the business alongside Hg.
According to a press release, Intelerad plans to use this investment and expertise to bolster innovation and operational excellence in order to maximize client business and health outcomes.
“Partnering with Hg gives us access to a huge pool of knowledge in global healthcare technology and the opportunity to significantly advance the company’s strategy,” said Paul Lepage, Intelerad’s chief executive officer.
Hg partner Gero Wittemann also reiterated Intelerad’s impact on the industry.
“Intelerad has a winning platform that creates significant efficiencies for healthcare organizations, while adding true value to help radiologists and other physicians view, interpret, and share medical images,” he said. “We fully embrace Intelerad’s vision in making a sustainable difference in healthcare.”
Intelerad specializes in diagnostic viewing, reporting, and collaboration solutions for radiologists and currently serves more than 300 healthcare organizations world-wide, including radiology groups, imaging center, clinics and reading groups.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.